Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine

Abstract

Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial growth is also disclosed comprising the step of administering the compositions of this invention to an animal including a human.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a group of compounds with anti-mycobacterial activities that have a common hydroxamic acid structural feature and to methods for using same. This invention also relates to compositions including an hydroxamate and an hydroxylamine which possess anti-mycobacterial activity and to methods for making and using same.

More particularly, the present invention relates to compositions capable of inhibiting mycobacterium tuberculosis in standard mycobacterial growth assays, where the compositions include a therapeutically effective amount of an hydroxamate or an therapeutically effective amount of an hydroxamate and an hydroxylamine and to methods for using same.

2. Description of the Related Art

With the rapid evolution of bacterial resistance to antibiotic therapy there is a constant need for new generations of drugs, and to attain this there is a need for new targets on which to focus the development of antibiotics. As part of a computer based drug design project we are addressing the development of novel inhibitors of the alanine racemase from various pathogenic organisms. This enzyme is required for the biosynthesis of the cell wall of all bacteria including mycobacteria. Because humans do not contain an alanine racemase gene, and do not have a use for this product, d-alanine, it is a logical target for the development of specific antibacterial agents.

You are in receipt of a series of publications that relate to the medical use of hydroxamate compounds. They describe the study of similar agents in malaria, cancer, toxin deactivation, and as t-RNA synthetase inhibitors. Some of these publications specifically refer to the use of hydroxamic acid and related compounds against tuberculosis. These references include, but are not limited to the following papers: (1) Gale, G. R. and. Hynes, J. B., “Further studies of the antimycobacterial agents glycyl laydroxamic acid and ˜-alanyl hydroxamie acid”(1966) Canadian J. Micro. (12), 73-81. (2) Gale, G. R. and Hawldns, J. E., “Antimycobacterial properties of glycyl hydroxamic acid and ˜-alanyl hydroxamic acid”, Am. Rev. Respiratory Dis. (92), 642-646.

Notably some of these compounds were shown in these reports to possess activity in animal models of tuberculosis and to lack significant toxicity. Following these types of studies it would be usual and customary to conduct confirmatory animal and toxicity studies. If these studies were promising, then human trials might be initiated. We have not as yet located the results of any further testing or trials for the compounds reported above.

Alanine racemase is necessary for cell wall biosynthesis in bacteria. Because humans do not have the alanine racemase gene and do not need the product it produces, it is a logical target for the development of specific antibacterial agents. Inhibitors of alanine racemase currently used (cycloserine) have neurological and other side effects because they are not specific to alanine racemase and inhibit the activity of other PLP-dependent enzymes. Cycloserine is currently used as a second-line drug against mycobacterium. Unfortunately, the use of cycloserine is limited because certain strains of mycobacterium have developed a resistance to it, and it has serious adverse effects including CNS toxicity and drug-induced psychosis. The need for new antibacterial agents that selectively inhibit only alanine racemase without causing side effects is obvious.

SUMMARY OF THE INVENTION

General Compositions

The present invention provides a composition having anti-mycobacterial activity including at least one hydroxamate.

The present invention provides a composition having anti-mycobacterial activity including at least one hydroxamate and at least one hydroxylamine.

The present invention provides a composition having anti-mycobacterial activity including a therapeutically effective amount of at least one hydroxamate.

The present invention provides a composition having anti-mycobacterial activity including a therapeutically effective amount of a combination of at least one hydroxamate and at least one hydroxylamine.

Specific Compositions

The present invention provides a composition having anti-mycobacterial activity including at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof, where:

• • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

The present invention provides a composition having anti-mycobacterial activity including at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof and at least one hydroxylamine having the general formula (II):H₂N—OR  (II)where:

• • R is selected from the group consisting of an hydrogen atom, a C1 alkyl group, C2 alkyl group, C3 alkyl group and C4 alkyl group;
  • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

The present invention provides a composition having anti-mycobacterial activity including a therapeutically effective amount of at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof, where:

• • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

The present invention provides a composition having anti-mycobacterial activity including a therapeutically effective amount of a combination of at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof and at least one hydroxylamine having the general formula (II):H₂N—OR  (II)where:

• • R is selected from the group consisting of an hydrogen atom, a C1 alkyl group, C2 alkyl group, C3 alkyl group and C4 alkyl group;
  • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.General Method for Treating Tuberculosis and Other Mycobacterial Infections

The present invention provides a composition having anti-mycobacterial activity including at least one hydroxamate.

The present invention provides a composition having anti-mycobacterial activity including at least one hydroxamate and an hydroxylamine.

The present invention provides a composition having anti-mycobacterial activity including a therapeutically effective amount of at least one hydroxamate.

The present invention provides a composition having anti-mycobacterial activity including a therapeutically effective amount of a combination of at least one hydroxamate and at least one hydroxylamine.

Specific Methods for Treating Tuberculosis and Other Mycobacterial Infections

The present invention provides a method for treating tuberculosis and other mycobacterial infections in animals including humans including the step of administering to an animal including a human on an individual, continuous, periodic, or intermittent basis or protocol, a composition having anti-mycobacterial activity including at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof, where:

• • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

The present invention also provides a method for treating tuberculosis and other mycobacterial infections in animals including humans including the step of administering to an animal including a human a composition having anti-mycobacterial activity including at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof and at least one hydroxylamine having the general formula (II):H₂N—OR  (II)where:

• • R is selected from the group consisting of an hydrogen atom, a C1 alkyl group, C2 alkyl group, C3 alkyl group and C4 alkyl group;
  • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower a alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic, lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

The present invention also provides a method for treating tuberculosis and other mycobacterial infections in animals including humans including the step of administering to an animal including a human a therapeutically effective amount of a compositions having anti-mycobacterial activity including at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof wherein:where:

• • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

The present invention also provides a method for treating tuberculosis and other mycobacterial infections in animals including humans including the step of administering to an animal including a human a therapeutically effective amount of a composition having anti-mycobacterial activity including a combination of at least one compound of general formula (I):

or pharmaceutically acceptable salts thereof and at least one hydroxylamine having the general formula (II):H₂N—OR  (II)where:

• • R is selected from the group consisting of an hydrogen atom, a C1 alkyl group, C2 alkyl group, C3 alkyl group and C4 alkyl group;
  • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have found that compounds based on a hydroxamic acid moiety are useful for the treatment of tuberculosis and other mycobacterial infections in animals including humans. The inventors have also found that combinations of those compounds with relatively small amount of hydroxyl amine having anti-mycobacterial activity and are useful for the treatment of tuberculosis and other mycobacterial infections in animals including humans.

The present invention broadly relates to compositions having anti-mycobacterial activity including between about 100 wt. % of at least one hydroxamate and about 0 wt. % of at least one hydroxylamine and about 50 wt. % of at least one hydroxamate and about 50 wt. % of at least one hydroxylamine. The hydroxamates can be optically pure, a racemic mixture of enantiomers, or an optically active mixture of enantiomers.

The present invention broadly relates to a method for treating mycobacteria including the step of administering a therapeutically effective amount of a composition including between about 100 wt. % of at least one hydroxamate and about 0 wt. % of at least one hydroxylamine and about 50 wt. % of at least one hydroxamate and about 50 wt. % of at least one hydroxylamine, where the at least one hydroxamate and at least one hydroxylamine can be co-administered or separately administered, with co-administration being preferred.

The administering step can be oral, inhalation, intravenous, intra-arterial, or mixtures or combinations of oral, inhalation, intravenous, or intra-arterial administrations. Preferably, the administering step is oral, inhalation and or mixtures or combinations of oral and inhalation administrations.

The hydroxamate compounds effective for use in this invention have the general formula (I):

or pharmaceutically acceptable salts thereof, where:

• • R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E is selected from the group consisting of CR⁵(R⁶), CH₂R⁵(R⁶), and CR⁵(R⁶)CH₂, where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof;
  • E′ is selected from the group consisting of O, S, or NR⁷;
  • E″ is NR⁷, where R⁷ is independently hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynyl, linear or branched aryl lower alkyl, linear or branched aryl, heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl, and mixtures or combinations thereof; and
  • n is an integer having a value between 1 and 4.

R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ may be independently unsubstituted or substituted, if substituted the substituents comprise at least one electron withdrawing substituent or at least one electron donating substituent selected from the group consisting of OR⁸, SR⁸, S(O)R⁸, S(O)₂R⁸, NH₂, NHR⁸, NR⁸(R⁹), NHNH₂, N(R⁸)NH₂, N(R⁸)N(R⁹)H, N(R⁸)N(R⁹)(R¹⁰), NOH, NOR⁸, C(O)R⁸, CO₂H, CO₂R⁸, CN, C(O)NH₂, C(O)NHR⁸, C(O)NR⁸(R⁹), OC(O)NH₂, OC(O)NHR⁸, OC(O)NR⁸(R⁹), C(NR⁸)N(H)R⁹, C(NR⁸)NR⁹(R¹⁰) and mixtures or combinations thereof, where R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

R⁸, R⁹ and R¹⁰ may be independently unsubstituted or substituted with at least one electron withdrawing or at least one electron donating substituent as defined for R^1-7.

Preferred compounds of formula (I) are selected from the group consisting of glycine hydroxamic acid, glycine hydroxamic acid hydrochloride, glycine hydroxamic trifluoracetic acid, O-methylglycine hydroxamic acid trifluoracetic acid, D-alanine hydroxamic acid hydrochloride, L-alanine hydroxamic acid hydrochloride, N-hydroxyoxalamide, sarcosine hydroxamic acid, D-methionine hydroxamic acid and mixtures or combinations thereof.

The hydroxylamine compounds effective for use in this invention have the general formula (II):H₂N—OR  (II)where R is selected from the group consisting of an hydrogen atom, a C1 alkyl group, C2 alkyl group, C3 alkyl group and C4 alkyl group. Preferably, R is an hydrogen atom, a methyl group or an ethyl group. The preferred hydroxyamines are H₂N—OH, MeHN—OH or EtHN—OH.

The anti-mycobacterial composition comprising an anti-mycobacterial effective amount of at least one compound of the general formula (I), in the absence or present of a hydroxyl amine of the general formula (II) can also include a pharmaceutical acceptable carrier.

As used herein, the term “pharmaceutically acceptable carrier” means an inert, non toxic solid or liquid filler, diluent or encapsulating material, not reacting adversely with the active compound or with the patient. Suitable, liquid pharmaceutically acceptable carriers are well known in the art such as sterile water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and or other similar carriers.

The formulations according to the invention may be administered as unit doses containing conventional non-toxic pharmaceutically acceptable carriers, diluents, adjuvants and vehicles which are typical for oral, inhalation, intravenous, or intra-arterial administration.

The compositions of this invention are administered to an animal including a human in the dose range between about 125 μg/mL and about 1 μg/mL for each hydroxamate or each hydroxylamine used in the compositions of this invention. Thus, for pure hydroxamate compositions, each hydroxamate is administered to an animal including a human in a dose range between about 125 μg/mL and about 1 μg/mL. While in a combination composition of at least one hydroxamate and at least one hydroxylamine, each hydroxamate and each hydroxylamine are administered to an an animal including a human in a dose range between about 125 μg/mL and about 1 μg/mL. Preferably, the ranges for each compound are independently between about 100 μg/mL and about 5 μg/mL. Particularly, the ranges for each compound are independently between about 100 μg/mL and about 25 μg/mL. The inventors have found that in the compositions including a combination of at least one hydroxamate and at least one hydroxylamine, the wt. % ratio of hydroxamate to hydroxylamine is generally between about 100:1 to about 1:1, preferably, between about 100:1 and 5:1 and particularly, between about 100:1 and about 10:1.

The inventors have tested several hydroxamates of this invention against M. tuberculosis, S. aureus, P. aeruginosa, and E. coli as set forth in Table A below. In Table A, In % refers to percent inhibition against the alanine racemase enzyme from each of the organisms; K_i refers to the inhibition constant in mM against the alanine racemase enzyme from each of the organisms; and MIC stands for “minimum inhibitory concentration” and refers to the concentration of compound that inhibits the growth of bacteria in a culture grown under standardized conditions. Not shown in the results of Table A, is the inhibitory activity of these compounds to the growth of tuberculosis in a TB bacterial growth assay. The TB bacterial growth assay results are set forth in Table B. While many of these compounds are strong inhibitors of alanine racemase, the inventors do not know if their anti-mycobacterial activity is due solely, or even primarily to inhibition of this target enzyme. In fact, in inventors have become aware that the original hydroxamate compounds tested all includes a small amount (about 1 wt. % or less) of hydroxylamine. The inventors have since discovered that the hydroxamate compounds originally tested had a small amount of hydroxylamine as a contaminate. Although hydroxylamine is known to inhibit bacterial growth by complexing with alanine racemase, the amount of hydroxylamine (about 1 μg/mL) is well below the effective dose range known for hydroxylamine which is about 125 μg/mL. Thus, the combination of an hydroxamate and an hydroxylamine appear to have a synergistic anti-myco-bacterial activity.

The inventors have used the structure of two alanine racemases (ALR) to aid in the design to new drugs that may be operable in inhibiting these enzymes. The two enzymes are from Pseudomoinas aeruginosa and Mycobacteriun tuberculosis as set forth below:

Pseudomonas aeruginosa ALR (Seq. ID No. 1):
MRPARALIDLQALRHNYRLAREATGARALAVIKADAYGHGAVRCAEALAA
EADGFAVACIEEGLELREAGIRQPILLLEGFFEASELELIVAHDFWCVVH
CAWQLEAIERASLARPLNVWLKMDSGMHRVGFFPEDFRAAHERLRASGKV
AKIVMMSHFSRADELDCPRTEEQLAAFSAASQGLEGEISLRNSPAVLGWP
KVPSDWVRPGILLYGATPFERAHPLADRLRPVMTLESKVISVRDLPAGEP
VGYGARYSTERRQRIGVVAMGYADGYPRHAADGTLVFIDGKPGRLVGRVS
MDMLTVDLTDHPQAGLGSRVELWGPMVPVGALAAQFGSIPYQLLCNLKRV
PRVYSGA
Mycobacterium tuberculosis ALR (Seq. ID No. 2):
MTPISQTPGLLAEAMVDLGAIEHNVRVLREHAGHAQLMAVVKADGYGHGA
TRVAQTALGAGAAELGVATVDEALALRADGITAPVLAWLHPPGIDFGPAL
LAQVAVSSLRQLDELLHAVRRTGRTATVTVKVDTGLNRNGVGPAQFPAML
TALRQAMAEDAVRLRGLMSHMVYADKPDDSINDVQAQRFTAFLAQAREQG
VRFEVAHLSNSSATMARPDLTFDLVRPGIAVYGLSPVPALGDMGLVPAMT
VKCAVALVKSIRAGEGVSYGHTWIAPRDTNLALLPIGYADGVFRSLGGRL
EVLINGRRCPGVGRICMDQFMVDLGPGPLDVAEGDEAILFGPGIRGEPTA
QDWADLVGTIHYEVVTSPRGRITRTYREAENR

Novel Features

The compositions of this invention have been prepared and tested at a time of heightened interest in developing new therapies for tuberculosis. The compositions are novel because they are not related to any of the compounds currently in use to treat tuberculosis, with the possible exception of cycloserine. Since we also have the crystal structure of alanine racemase from tuberculosis, the structure can be use as an aid in the optimization of compound activity. Because these compounds have not been in clinical use, it is likely that the composition of this invention will be active against almost all strains, including drug resistant strains of tuberculosis.

The critical features of ALR that will aid in the development of improved anti-myco-bacterial compositions include the following atoms from the crystal structure of Pseudomonas aeruginosa ALR that relate to the active site of the enzyme:

CRYST1  72.679  76.129  136.266 90.00 90.00 90.00 C 2 2 21  4
SCALE1    0.013759  0.000000  0.000000     0.00000
SCALE2    0.000000  0.013136  0.000000     0.00000
SCALE3    0.000000  0.000000  0.007339     0.00000
ATOM	1	N1	PLP	358	5.890	25.908	17.398	1.000	16.57
ATOM	2	C2	PLP	358	5.860	25.384	16.144	1.000	16.64
ATOM	3	C2A	PLP	358	5.833	23.858	15.961	1.000	15.86
ATOM	4	C3	PLP	358	5.728	26.198	15.064	1.000	16.74
ATOM	5	O3	PLP	358	5.626	25.679	13.823	1.000	18.80
ATOM	6	C4	PLP	358	5.624	27.574	15.216	1.000	16.59
ATOM	7	C5	PLP	358	5.652	28.096	16.527	1.000	16.37
ATOM	8	C6	PLP	358	5.782	27.240	17.566	1.000	15.48
ATOM	9	C5A	PLP	358	5.480	29.604	16.770	1.000	16.20
ATOM	10	OP4	PLP	358	4.086	29.941	16.633	1.000	16.19
ATOM	11	P	PLP	358	3.525	31.402	17.008	1.000	16.27
ATOM	12	OP1	PLP	358	4.174	32.346	16.064	1.000	16.84
ATOM	13	OP2	PLP	358	2.065	31.338	16.836	1.000	17.82
ATOM	14	OP3	PLP	358	3.918	31.635	18.427	1.000	14.85
ATOM	15	C4AA	PLP	358	6.056	28.506	14.061	0.500	16.24
ATOM	16	C4BB	PLP	358	4.823	28.510	14.300	0.500	26.88
ATOM	17	N	DLY	359	3.417	26.795	12.294	1.000	48.57
ATOM	18	CA	DLY	359	3.917	27.532	11.149	1.000	27.53
ATOM	19	C	DLY	359	4.689	26.599	10.228	1.000	43.00
ATOM	20	OT1	DLY	359	5.778	26.145	10.662	1.000	56.73
ATOM	21	OT2	DLY	359	4.266	26.271	9.107	1.000	42.97
ATOM	22	CB	DLY	359	2.854	28.394	10.504	1.000	27.08
ATOM	23	CG	DLY	359	2.816	29.839	10.957	1.000	52.76
ATOM	24	CD	DLY	359	3.842	30.116	12.044	1.000	64.94
ATOM	25	CE	DLY	359	3.200	30.029	13.419	1.000	72.55
ATOM	26	NZ	DLY	359	3.562	28.764	14.116	1.000	61.63
ATOM	27	N	MET	1	18.287	57.694	−3.207	1.000	29.47
ATOM	28	CA	MET	1	17.812	56.421	−2.685	1.000	24.27
ATOM	29	C	MET	1	16.294	56.389	−2.548	1.000	19.19
ATOM	30	O	MET	1	15.682	57.358	−2.103	1.000	21.13
ATOM	31	CB	MET	1	18.456	56.139	−1.325	1.000	30.26
ATOM	32	CG	MET	1	17.797	55.000	−0.564	1.000	33.61
ATOM	33	SD	MET	1	18.979	53.704	−0.153	1.000	44.73
ATOM	34	CE	MET	1	17.950	52.294	0.249	1.000	31.76
ATOM	35	N	ARG	2	15.665	55.245	−2.812	1.000	18.73
ATOM	36	CA	ARG	2	14.263	55.112	−2.465	1.000	17.06
ATOM	37	C	ARG	2	14.035	55.237	−0.953	1.000	16.99
ATOM	38	O	ARG	2	14.758	54.626	−0.180	1.000	17.64
ATOM	39	CB	ARG	2	13.812	53.752	−2.933	1.000	19.81
ATOM	40	CG	ARG	2	12.363	53.440	−3.086	1.000	20.60
ATOM	41	CD	ARG	2	12.128	52.127	−3.844	1.000	19.07
ATOM	42	NE	ARG	2	10.706	51.722	−3.737	1.000	18.62
ATOM	43	CZ	ARG	2	10.203	50.677	−3.083	1.000	14.10
ATOM	44	NH1	ARG	2	10.963	49.822	−2.376	1.000	15.34
ATOM	45	NH2	ARG	2	8.907	50.427	−3.081	1.000	14.97
ATOM	46	N	PRO	3	13.058	56.003	−0.475	1.000	16.64
ATOM	47	CA	PRO	3	12.883	56.212	0.971	1.000	16.35
ATOM	48	C	PRO	3	12.259	55.083	1.772	1.000	16.34
ATOM	49	O	PRO	3	12.098	55.184	2.996	1.000	21.50
ATOM	50	CB	PRO	3	12.033	57.493	1.009	1.000	16.82
ATOM	51	CG	PRO	3	11.229	57.444	−0.241	1.000	16.82
ATOM	52	CD	PRO	3	12.142	56.829	−1.265	1.000	16.35
ATOM	53	N	ALA	4	11.947	53.947	1.181	1.000	14.96
ATOM	54	CA	ALA	4	11.341	52.821	1.871	1.000	15.34
ATOM	55	C	ALA	4	12.302	52.203	2.870	1.000	14.62
ATOM	56	O	ALA	4	13.483	52.046	2.539	1.000	16.72
ATOM	57	CB	ALA	4	10.965	51.796	0.820	1.000	17.08
ATOM	58	N	ARG	5	11.847	51.797	4.051	1.000	15.38
ATOM	59	CA	ARG	5	12.686	51.031	4.965	1.000	14.99
ATOM	60	C	ARG	5	11.840	50.367	6.026	1.000	14.32
ATOM	61	O	ARG	5	10.691	50.764	6.272	1.000	16.25
ATOM	62	CB	ARG	5	13.722	51.903	5.649	1.000	18.93
ATOM	63	CG	ARG	5	13.140	53.035	6.462	1.000	21.76
ATOM	64	CD	ARG	5	14.305	53.898	6.985	1.000	23.36
ATOM	65	NE	ARG	5	13.785	54.861	7.912	1.000	25.27
ATOM	66	CZ	ARG	5	14.522	55.670	8.678	1.000	30.80
ATOM	67	NH1	ARG	5	15.840	55.668	8.643	1.000	34.01
ATOM	68	NH2	ARG	5	13.925	56.509	9.500	1.000	42.52
. . . portion of PDB file omitted . . .
ATOM	2727	N	PRO	351	15.513	48.173	2.901	1.000	15.90
ATOM	2728	CA	PRO	351	16.496	47.975	3.960	1.000	15.31
ATOM	2729	C	PRO	351	15.862	47.730	5.331	1.000	14.58
ATOM	2730	O	PRO	351	14.835	48.314	5.641	1.000	16.93
ATOM	2731	CB	PRO	351	17.246	49.311	4.012	1.000	17.92
ATOM	2732	CG	PRO	351	16.845	50.112	2.840	1.000	19.24
ATOM	2733	CD	PRO	351	15.554	49.521	2.317	1.000	15.27
ATOM	2734	N	ARG	352	16.530	46.904	6.153	1.000	15.45
ATOM	2735	CA	ARG	352	16.182	46.680	7.535	1.000	14.79
ATOM	2736	C	ARG	352	17.214	47.392	8.423	1.000	15.43
ATOM	2737	O	ARG	352	18.405	47.110	8.306	1.000	17.05
ATOM	2738	CB	ARG	352	16.107	45.196	7.917	1.000	17.79
ATOM	2739	CG	ARG	352	14.884	44.533	7.270	1.000	21.42
ATOM	2740	CD	ARG	352	14.826	43.057	7.563	1.000	22.14
ATOM	2741	NE	ARG	352	16.007	42.379	7.024	1.000	24.75
ATOM	2742	CZ	ARG	352	16.108	41.064	6.937	1.000	21.96
ATOM	2743	NH1	ARG	352	15.103	40.316	7.342	1.000	22.29
ATOM	2744	NH2	ARG	352	17.160	40.434	6.462	1.000	30.10
ATOM	2745	N	VAL	353	16.684	48.329	9.199	1.000	15.42
ATOM	2746	CA	VAL	353	17.532	49.153	10.054	1.000	14.57
ATOM	2747	C	VAL	353	17.265	48.779	11.500	1.000	14.52
ATOM	2748	O	VAL	353	16.192	49.007	12.011	1.000	16.43
ATOM	2749	CB	VAL	353	17.293	50.661	9.786	1.000	16.74
ATOM	2750	CG1	VAL	353	18.267	51.473	10.621	1.000	19.72
ATOM	2751	CG2	VAL	353	17.435	50.941	8.302	1.000	22.47
ATOM	2752	N	TYR	354	18.221	48.143	12.158	1.000	14.94
ATOM	2753	CA	TYR	354	18.111	47.660	13.517	1.000	16.61
ATOM	2754	C	TYR	354	18.477	48.773	14.511	1.000	17.12
ATOM	2755	O	TYR	354	19.434	49.531	14.345	1.000	20.50
ATOM	2756	CB	TYR	354	18.984	46.409	13.732	1.000	15.78
ATOM	2757	CG	TYR	354	18.537	45.287	12.828	1.000	15.23
ATOM	2758	CD1	TYR	354	17.571	44.377	13.216	1.000	15.73
ATOM	2759	CD2	TYR	354	19.090	45.186	11.561	1.000	16.56
ATOM	2760	CE1	TYR	354	17.192	43.379	12.338	1.000	14.50
ATOM	2761	CE2	TYR	354	18.715	44.192	10.690	1.000	18.11
ATOM	2762	CZ	TYR	354	17.765	43.294	11.099	1.000	17.22
ATOM	2763	OH	TYR	354	17.359	42.288	10.256	1.000	18.94
ATOM	2764	N	SER	355	17.672	48.840	15.568	1.000	16.89
ATOM	2765	CA	SER	355	18.007	49.645	16.722	1.000	20.52
ATOM	2766	C	SER	355	17.977	48.806	17.995	1.000	20.37
ATOM	2767	O	SER	355	17.297	47.796	18.086	1.000	20.84
ATOM	2768	CB	SER	355	17.056	50.820	16.872	1.000	22.59
ATOM	2769	OG	SER	355	15.778	50.355	17.249	1.000	32.04
ATOM	2770	N	GLY	356	18.726	49.230	19.000	1.000	22.99
ATOM	2771	CA	GLY	356	18.698	48.525	20.275	1.000	23.83
ATOM	2772	C	GLY	356	19.620	47.327	20.321	1.000	25.32
ATOM	2773	O	GLY	356	19.512	46.472	21.211	1.000	34.87
ATOM	2774	N	ALA	357	20.569	47.203	19.393	1.000	27.11
ATOM	2775	CA	ALA	357	21.436	46.025	19.422	1.000	42.24
ATOM	2776	C	ALA	357	22.377	45.978	20.628	1.000	45.72
ATOM	2777	O	ALA	357	22.787	47.023	21.163	1.000	38.82
ATOM	2778	CB	ALA	357	22.226	45.967	18.121	1.000	46.64
ATOM	2779	OT2	ALA	357	22.708	44.837	21.025	1.000	58.13
. . . portion of PDB file omitted . . .
ATOM	3089	OW0	WAT	839	10.655	56.476	12.115	1.000	42.28
ATOM	3090	OW0	WAT	840	2.151	47.888	23.618	1.000	47.09
ATOM	3091	OW0	WAT	842	20.550	51.874	14.686	1.000	33.45
ATOM	3092	OW0	WAT	843	22.114	9.974	2.401	1.000	44.24
ATOM	3094	OW0	WAT	845	6.672	70.712	−6.117	1.000	37.20
ATOM	3095	OW0	WAT	846	22.893	9.953	7.913	1.000	48.39
ATOM	3096	OW0	WAT	847	19.552	31.453	30.000	1.000	43.42
ATOM	3097	OW0	WAT	848	−8.507	12.416	25.018	1.000	46.62
ATOM	3098	OW0	WAT	851	13.421	−0.795	19.395	1.000	42.34

The critical features of Mycobacterium tuberculosis ALR are similar and can also aid in the design of new anti-mycobacterial compositions.

Hydroxamates: General Preparation and Purification

The hydroxamates of this invention are relatively simple to prepare and purify. For the most part, the hydroxamates of this invention appear to be stable over time. The hydroxamates of this invention are also novel because they are active against mycobacteria, but not Gram positive or Gram negative bacteria. As a result, the hydroxamates of this invention are not likely to cause side adverse effects such as the elimination of normal bacterial populations in the treated host.

Testing has been done for a number of compounds of general formula (I) as inhibitors of alanine racemase and as inhibitors of bacterial growth. The results of this testing are shown in the Tables A, B and C. Note that several of the compounds are strong inhibitors of alanine racemase. Note that, in growth assays, the compounds possess no appreciable activity against S. aureus, P. aeruginosa, and E. coli, but several possess activity against M. tuberculosis that approximates the activity of cycloserine. Please note that although many of these compounds are strong inhibitors of alanine racemase, we do not know if their anti-mycobacterial activity is due solely, or even primarily to inhibition of this target. For that further testing will be required.

Results

The testing results are listed in the following tables for the indicated hydroxamate compounds. These test results include the indicated hydroxamate with an approximate 1 wt. % hydroxylamine contaminant, which was discovered after the original testing results were obtained. The inventors believe that the two compounds, the hydroxamate and the hydroxylamine, work in a synergistic manner to inhibit mycobacterial growth, because hydroxylamine is effect at doses of about 100 μg/mL, while the compositions of this invention show anti-mycobacterial activity an hydroxylamine doses of ≧1 μg/mL.

TABLE A
Inhibition and MIC data (% Inhibition at 2.5 mM, Ki [mM] and MIC[mM])
	M.
	tuberculosis	S. aureus	P. aeruginosa	E. Coli
Structure	In %	Ki	In %	Ki	MIC	In %	Ki	In %	Ki	MIC	Remark
H2NCH2C(O)NHOH	100 ± 1	0.008	91 ± 3	0.090	>0.5	94 ± 1	0.065	90 ± 5	0.039	>5	Free base
H2NOH2G(O)NHOH	100 ± 2	0.031	92 ± 3	0.034	>5	90 ± 2	0.033	90 ± 4	0.075	>5	Add 1 eq
											of TFA
H~1H2NGHa~(O)NHOH	105 ± 6	0.195	95 ± 1	0.217	>5	114 ± 14	0.201	88 ± 4	0.268	>5	I-ICI salt
TFA•H2NCH2G(O)NHOH	104 ± 4	0.022	99 ± 3	0.023	>5	112 ± 7	0.020	94 ± 4	0.078	>5	TFA salt
TFA•H2NGH2G(O)N(GHa)OH	60 ± 3	0.786	57 ± 3	0.840	>5	62 ± 4	0.802	52 ± 3	0.866	>5
TFA•H2NGH2C(O)NHOCH3	66	1.386	47	1.845	>5	55	1.507	67	1.337	>5
TFA•H2N~H2~(O)N(GHa)OGHa	66 ± 4	0.644	66 ± 3	0.590	>5	68 ± 5	0.633	49 ± 2	0.875	>5
HzNGH(~Ha)G(O)NHOH	48 ± 9	0.867	57 ± 4	0.810	>5	66 ± 3	0.656	58 ± 2	0.756	>5	DL-alanine
HGI•H~NGH(OHa)O(O)NHOH	70 ± 11	0.705	33 ± 6	2.675	>5	29 ± 6	1.011	35 ± 7	5.204	>5	D-isomer
HGI•HaNGH(GHa)G(O)NHOH	59 ± 7	0.689	32 ± 8	1.299	>5	33 ± 2	1.060	39 ± 8	2.780	>5	L-isomer
H2NC(O)NHOH	22 ± 8	ND	12 ± 7	ND	>5	10 ± 4	ND	0 ± 12	ND	>5
Hg1HzNGHz~Hzg(O)NHOH	79 ± 12	0.629	49 ± 12	0.401	>5	34 ± 9	0.894	37 ± 10	1.206	>5	L-alanine
H2NC(O)C(O)NHOH	93 ± 8	0.032	97 ± 0	0.017	>5	99 ± 4	0.016	97 ± 4	0.052	>5	Oxamic acid
CH3NHCH2C(O) NHOH	81 ± 7	1.386	28 ± 5	14.345	>5	24 ± 5	18.165	34 ± 12	5.696	>5
H2NCH(CH2OH)C(O)NHOH	33 ± 8	3.20	19 ± 8	7.20	>5	28 ± 5	5.10	0 ± 4	ND	>5	DL-serine
TFA•HzNCH(CH2OH)C(O)N HOCH3	48 ± 10	ND	55 ± 2	ND	ND	24 ± 5	ND	28 ± 12	ND	ND	DL-serine
H2NCH(CH2CHaSCH3)C(O)NHOH	0 ± 4	ND	1 ± 3	ND	>5	7 ± 4	~D	0 ± 6	ND	ND	DL-
											methionin
PhCH2NHGH2C(O)NHOH	88 ± 3	0.519	53 ± 13	1.976	>5	39 ± 9	1.243	0.58 ± 3	1.838	>5
H2NCH(CH2OCONH2)C(O)NILIOH	97 ± 5	0.030	93 ± 4	0.056	>5	94 ± 5	0.030	96 ± 8	0.008	>5
D-cycloserine	93	0.01	94	0.01	0.2	95	0.01	93	0.01		Control

TABLE B
TB Assay of Hydroxamate Candidates
	% In	Days of
Compound	in TB-ALR-assay	Detection
DMSO	0	7
Water	0	8
HCl•H2NCH2CH2C(O)NHOH	79	8.5
TFA•H2NCH2C(O)N(CH3)OH	60	9
TFA•H2NCH2C(O)N(CH3)OCH	66	9
H2NC(O)NHOH	22	9
TFA•H2NCH(CH2OH)C(O)NHOCH3	48	9
HCl•H2NCH2(O)NHOH	100	16.5
HCl•H2NCH(CH3)C(O)NHOH*	59	17.5
PhCH2NHCH2C(O)NHOH	88	18.5
H2NCH(CH2OH)C(O)NHOH	33	21.5
Hcl•H2NCH(CH3)C(O)NHOH	70	22.5
H2NC(O)C(O)NHOH	93	32
CH3NHCH2C(O)NHOH	81	32.5
H2NCH2C(O)NHOH	100	>40
TFA•H2NCH2C(O)NHOCH3	66	>40
H2NCH(CH2CH2SCH3)C(O)NHOH	0	>40
D-Cycloserine	96	>40

TABLE C
Result of MGIT Assay
Compound                   MIC [μg/ml]
TFA•H2NCH2C(O)NHOCH3       50
H2NCH2C(O)NHOH             50
H2NC(O)C(O)NHOH            50
CH3NHCH2C(O)NHOH           200
HCl•H2NCH(CH3)C(O)NHOH     100
HCl•H2NCH(CH3)C(O)NHOH     50
HCl•H2NCH2C(O)NHOH         200
H2NCH(CH2OH)C(O)NHOH       100
PhCH2NHCH2C(O)NHOH         50
H2NC(O)NHOH                >200
HCl•H2NCH2CH2C(O)NHOH      >200
HCl•H2NCH2CH2C(O)NHOH      >200
TFA•H2NCH(CH2OH)C(O)NHOCH3 >200
TFA•H2NCH2C(O)N(CH3)OCH3   >200
D-Cycloserine              <12.5

EXPERIMENTAL SECTION

General Method

Melting points were determined with a Thomas-Hoover melting point apparatus and were uncorrected. ¹H and ¹³C NMR spectra were taken on a Varian VXR 300 and Bruker DRX z100 NMR instruments. Chemical shifts (b) are in parts per million (ppm) relative to tetramethylsilane, and coupling constants (J values) are in Hertz. Low- and high-resolution (CI) mass spectral investigations were conducted at the University of Texas at Austin by Dr. M. Moini. The low-resolution mass studies were run on a Finnegan MAT-TSQ-70 instrument and the high, resolution mass studies were conducted on a Micromass ZAB-E spectrometer. The solvents and reactants were of the best commercial grade available and were used without further purification unless noted. Thin-layer chromatography was run on precoated silica gel GHLF (10×20 cm; Aldrich No. Z27428-3).

General Coupling Procedure Using CDI for the BOC-Hydroxamie Acids (13-18, 22)

A solution of the butoxycarbonyl (BOC)-amino acid (1 equiv) in dry tetrahydrofuran (THF) (1.0-1.5 mL/1 mmol of BOC-amino acid) was added to a solution of carbonyldiimidazole (1 equiv) in a dry THF (3.0 mL/1 mmol of CDI). The reaction solution was stirred at room temperature (30 min), heated to reflux (30 rain), and cooled to room temperature. The desired hydroxylalrfine (1 equiv) was added to the reaction and the suspension was stirred (12-18 h). The solid was filtered and the filtrate diluted with ethylacetate (EtOAc) (10 mL), and washed successively with aqueous 2 N HCl (5 mL), saturated aqueous NaHCO₃ solution (10 mL), and H20 (5 mL). The EtOAc layer was dried magnesium sulfate (MgSO₄) and concentrated in vacuo. The residue was purified by PTLC (5-10% MeOH—CHCl₃) to afford the desired hydroxamic acid, where MeOH represent methanol.

N-(tert-Butoxycarbonyl)glycine Hydroxamic Acid (13)

Yield, 42%; R_f=0.35 (10% MeOH—CHCl₃); mp 117-119° C. (lit.¹⁾ mp 115-117° C.); ¹H NMR (CD₃OD, 300 MHz) δ1.44 (s, 9H), 3.66 (s, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ28.7 (3 C), 42.6, 80.8, 158.4, 169.5; MS (+CI) 191 [M+1]⁺; M_r(+CI) 191.103 29 [M+1]⁺ (calcd for C₇H₁₅N₂O₄, 191.103 18).

N′-Methyl-N-(tert-butoxycarbonyl)glycine Hydroxamic Acid (14)

Yield, 28%; R_f=0.65 (10% MeOH—CHCl₃); mp 98-100° C.; ¹H NMR (CD₃OD, 300 MHz) δ1.44 (s, 9H), 3.19 (s, 3H), 3.98 (s, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ28.7 (3 C), 36.5, 42.3, 80.5, 158.7, 171.8.

O-Methyl-N-(tert-butoxycarbonyl)glycine Hydroxamic Acid (15)

Yield, 35% as a semi-solid; R_f=0.56 (10% MeOH—CHCl₃); ¹H NMR (CD₃OD, 300 MHz) δ1.45 (s, 9H), 3.64 (s, 2H), 3.69 (s, 3H); ¹³C NMR (CD₃OD, 75 MHz) δ28.7 (3 C), 42.7, 64.4, 80.8, 158.4, 169.4; MS (+CI) 205 [M+1]⁺; M_r (+CI) 205.117 88 [M+1]⁺ (calcd for C₈H₁₇N₂O₄, 205.118 83).

N-(tert-Butoxycarbonyl)-D-alanine Hydroxamic Acid (16)

Yield, 27%; R_f=0.37 (10% MeOH—CHCl₃); mp 115-117° C.; ¹H NMR (CD₃OD, 300 MHz) δ1.29 (d, J=7.2 Hz, 3H), 1.43 (s, 9H), 4.00 (q, J=7.2 Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz) δ18.6, 28.7 (3 C), 49.4, 80.6, 157.5, 172.7.

N-(tert-Butoxycarbonyl)-L-alanine Hydroxamic Acid (17)

Yield, 28%; R_f=0.37 (10% MeOH—CHCl₃); mp 116-118° C.; ¹H NMR (CD₃OD, 300 MHz) δ1.29 (d, J=7.2 Hz, 3H), 1.43 (s, 9H), 4.00 (q, J=7.2 Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz) δ18.6, 28.7 (3 C), 49.4, 80.6, 157.5, 172.7.

N-(tert-Butoxycarbonyl)-β-alanine Hydroxamic Acid (18)

Yield, 25%; R_f=0.28 (10% MeOH—CHCl₃); mp 85-87° C.; IR (KBr) 3323, 3239, 3062, 2977, 1687, 1634, 1540, 1431, 1368, 1292, 1179, 1037 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ1.42 (s, 9H), 2.27 (t, J=6.6 Hz, 2H), 3.30 (t, J=6.6 Hz, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ28.8 (3 C), 34.1, 37.9, 80.2, 158.3, 170.8; MS (+CI). 205 [M+1]⁺; M_r (+CI) 205.117 83 [M+1]⁺ (calcd for C₈H₁₇N₂O₄, 205.118 83). Anal. (C₈H₁₆N₂O₄.0.1H₂O) C, 46.64; H, 7.92; N, 13.60. Found C, 46.79; H, 7.97; N, 13.28.

N-(tert-Butoxycarbonyl)-D-methionone Hydroxamic Acid (22)

Yield, 31%; R_f=0.47 (10% MeOH—CHCl₃); mp 129-131° C.; ¹H NMR (CD₃OD, 300 MHz) δ1.44 (s, 9H), 1.83-2.00 (m, 2H), 2.08 (s, 3H), 2.47-2.54 (m, 2H), 4.09 (t, J=6.3 Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz) δ15.3, 28.7 (3 C), 31.1, 33.1, 52.9, 80.7, 157.7, 171.4; MS (+CI) 265 [M+1]⁺; M_r (+CI) 265.122 48 [M+1]⁺ (calcd for C₁₀H₂₁N₂O₄S, 265.122 20).

General Coupling Procedure Using DCC for the BOC-Hydroxamic Acids (19-20)

To a THF (2 mL/1 mmol of amino acid) solution of the BOC-amino acid (1 equiv) was added a solution of hydroxylamine hydrochloride (2 equiv) in a H₂O (4 mL/1 mmol of hydroxylamine). The pH was maintained at 4.5-5.0 while a THF (3 mL/1 mmol of DCC) solution of DCC (2 equiv) was added with stirring (1-5 h). The solid was filtered and the filtrate was concentrated in vacuo. The residue was purified by PTLC (EtOAc/hexanes) to afford the desired hydroxamic acid.

O-Methyl-N-(tert-butoxycarbonyl)-D-serine Hydroxamic Acid (19)

Yield, 46%; R_f=0.41 (10% MeOH—CHCl₃); mp 83-85° C. (lit.⁴⁾ mp 84-86° C.); ¹H NMR (CD₃OD, 400 MHz) δ1.45 (s, 9H), 3.69 (s, 3H), 3.70 (d, J=3.9 Hz, 2H), 4.02 (t, J=3.9 Hz, 1H); ¹³C NMR (CD₃OD, 100 MHz) δ28.7 (3 C), 56.1, 63.0, 64.4, 80.9, 157.7, 170.0; MS (+CI) 235 [M+1]⁺; M_r (+CI) 235.128 46 [M+1]⁺ (calcd for C₉H₁₉N₂O₅, 235.129 39).

O-Benzyl-N-(tert-butoxycarbonyl)-D-serine Hydroxamic Acid (20)

Yield, 54%; R_f=0.66 (10% MeOH—CHCl₃); mp 128-130° C. (lit.⁵⁾ mp 130-131° C. for L-isomer); IR (KBr) 3359, 3190, 2993, 2933, 1710, 1668, 1512, 1400, 1252, 1168, 1067 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ1.44 (s, 9H), 3.67 (d, J=5.4 Hz, 2H), 4.03 (t, J=5.4 Hz, 1H), 4.84 (s, 2H), 7.33-7.45 (m, 5H); ¹³C NMR (CD₃OD, 75 MHz) δ28.7 (3 C), 56.1, 63.2, 79.2, 80.9, 129.5, 129.7 (2 C), 130.5 (2 C), 136.9, 157.6, 170.2; MS (+CI) 311 [M+1]⁺; M_r (+CI) 311.160 52 [M+1]⁺ (calcd for C₁₅H₂₃N₂O₅, 311.160 69).

N-(tert-Butoxycarbonyl)-D-serine Hydroxamic Acid (21)

A solution of 20 (137 mg, 0.44 mmol) in EtOH (7 mL) containing 10% Pd—C (46 mg) was hydrogenated at 1 atm (1.5 h). The catalyst was filtered and the filtrate was concentrated in vacuo, and then crystallized with isopropyl ether to afford 21 as a solid. Yield, 81%; R_f=0.19 (10% MeOH—CHCl₃); mp 108-110° C. (lit.⁶⁾ mp 106-112° C. for L-isomer); IR (KBr) 3421, 3318, 2871, 1726, 1670, 1514, 1370, 1243, 1160 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ1.44 (s, 9H), 3.69 (d, J=5.4 Hz, 2H), 4.06 (t, J=5.4 Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz) δ28.7 (3 C), 56.1, 63.2, 80.9, 157.6, 170.1; MS (+CI) 221 [M+1]⁺; M_r (+CI) 221.113 90 [M+1]⁺ (calcd for C₈H₁₇N₂O₅, 221.113 74).

General Procedure for Removal of the BOC Group.

(1) Using HCl/EtOAc.

AnEtOAC (3.8-4.0 mL/1 mmol of BOC-hydroxamic acid) solution of HCl prepared from acetyl chloride (8 equiv) and EtOH (8 equiv) was added to the BOC-hydroxamic acid (1 equiv), and the reaction was stirred at room temperature (15-18 h). The solid was filtered, and washed with EtOAc to afford the hydroxamic acid as a HCl salt.

(2) Using Trifluoroacetic Acid.

The BOC-hydroxamic acid (1 equiv) was dissolved in TFA (1.0-1.2 mL/1 mmol of the BOC-hydroxamic acid) and stirred at room temperature (30 min). The TFA salt was precipitated by addition of ethyl ether or isopropyl ether. The solid was filtered and washed with isopropyl ether (5 mL), and dried in vacuo to yield the hydroxamic acid as a TFA salt. Compounds 3, 5 and 9 were obtained as either an oil or a semi-solid.

Glycine Hydroxamic Acid Hydrochloride (2)

Yield, 73%; mp 103-106° C. (lit.⁷⁾ mp 108-109° C.); ¹H NMR (CD₃OD, 300 MHz) δ3.92 (s, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ39.5, 164.9; MS (+CI) 91 [(M—HCl)+1]⁺; M_r (+CI) 91.050 60 [(M—HCl)—H]⁺ (calcd for C₂H₇N₂O₂, 91.050 75).

N-Methylglycine Hydroxamic Acid Trifluoroacetic Acid (3).¹⁾

Yield, 85% as a semi-solid; ¹H NMR (CD₃OD, 300 MHz) δ3.25 (s, 3H), 3.93 (s, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ36.4, 40.7, 163.3, 167.5; MS (+CI) 105 [(M—TFA)+1]⁺; M_r (+CI) 104.058 41 [M—TFA]⁺ (calcd for C₃H₈N₂O₂, 104.058 58).

O-Methylglycine Hydroxamic Acid Trifluoroacetic Acid (4)

Yield, 78%; mp 114-116° C. (lit.¹⁾ mp 113-114° C.); ¹H NMR (DMSO-d₆, 300 MHz) δ3.49 (s, 2H), 3.64 (s, 3H), 3.84 (s, 1H), 8.38 (br s, 2H); ¹³C NMR (DMSO-d₆, 75 MHz) δ38.1, 63.5, 163.1; MS (+CI) 105 [(M—TFA)+1]⁺; M_r (+CI) 105.065 91 [(M—TFA)+1]⁺ (calcd for C₃H₉N₂O₂, 105.066 40).

N,O-Methylglycine Hydroxamic Acid Trifluoroacetic Acid (5).¹⁾

Yield, 81% as a semi-solid; ¹H NMR (CD₃OD, 300 MHz) δ3.23 (s, 3H), 3.77 (s, 3H), 3.98 (s, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ32.5, 40.8, 62.2, 168.2; MS (+CI) 119 [(M—TFA)+1]⁺; M_r (+CI) 118.074 31 [M—TFA]⁺ (calcd for C₄H₁₀N₂O₂, 118.074 23).

D-Alanine Hydroxamic Acid Hydrochloride (6)

Yield, 95%; mp 179-181° C. (lit.⁸⁾ mp 183-184° C. for the racemate); IR (KBr) 3177, 2997, 1677, 1566, 1532, 1487, 1389, 1180, 1037 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ1.50 (d, J=7.2 Hz, 3H), 3.88 (q, J=7.2 Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz) δ17.8, 48.4, 168.4; MS (+CI) 105 [(M—HCl)+1]⁺; M_r (+CI) 105.065 98 [(M—HCl)+1]⁺ (calcd for C₃H₉N₂O₂, 105.066 40). Anal. (C₃H₈N₂.1.1HCl.0.05 EtOAc) C, 25.86; H, 6.44; N, 18.85. Found C, 25.78; H, 6.46; N, 18.87.

L-Alanine Hydroxamic Acid Hydrochloride (7)

Yield, 94%; mp 178-180° C. (lit.⁸⁾ mp 183-184° C. for the racemate); IR (KBr) 3180, 1681, 1610, 1568, 1492, 1393, 1270, 1213, 1138, 1039 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ1.50 (d, J=7.2 Hz, 3H), 3.89 (q, J=7.2 Hz, 1H); ¹³C NMR (CD₃OD, 75 MHz) δ17.8, 48.4, 168.4; MS (+CI) 105 [(M—HCl)+1]⁺; M_r (+CI) 105.066 02 [(M—HCl)+1]⁺ (calcd for C₃H₉N₂O₂, 105.066 40). Anal. (C₃H₈N₂O₂.1.1HCl.0.1 EtOAC) C, 26.69; H, 6.52; N, 18.30. Found C, 26.52; H, 6.50; N, 18.61.

β-Alanine Hydroxamic Acid Hydrochloride (8)

Yield, 85%; mp 140-142° C. (lit.⁷⁾ mp 144° C.), ¹H NMR (CD₃OD, 300 MHz) δ2.33 (t, J=6.6 Hz, 2H), 3.01 (t, J=6.6 Hz, 2H); ¹³C NMR (CD₃OD, 75 MHz) δ30.1, 37.1, 169.4; MS (+CI) 105 [(M—HCl)+1]⁺; M_r (+CI) 105.065 88 [(M—HCl)+1]⁺ (calcd for C₃H₉N₂O₂, 105.066 40).

O-Methyl-D-serine Hydroxamic Acid Trifluoroacetic Acid (9)

Yield, 80% as a semi-solid; IR (neat) 3450, 1681, 1525, 1439, 1142, 1052 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ3.74 (s, 3H), 3.78-3.92 (m, 2H), 4.37 (t, J=3.9 Hz, 1H); ¹³C NMR (CD₃OD, 100 MHz) δ54.3, 61.6, 64.7, 165.6; MS (+CI) 135 [(M—TFA)+1]⁺; M_r (+CI) 135.076 18 [(M—TFA)+1]⁺ (calcd for C₄H₁₁N₂O₃, 135.076 96). Anal. (C₄H₁₀N₂O₃.1.1 CF₃CO₂H.0.2H₂O) C, 28.30; H, 4.40; N, 10.64. Found C, 28.24; H, 4.60; N, 10.46.

General Coupling Procedure for the Hydroxamic Acid (10-12)

To an absolute MeOH (0.5-1.0 mL/1 mmol of ethyl ester) solution of ethyl ester (1 equiv) was added an absolute MeOH (0.7-1.0 mL/1 mmol of hydroxylamine hydrochloride) solution of hydroxylamine prepared from hydroxylamine hydrochloride (1.5 equiv) and KOH (1.5 equiv). The reaction mixture was stirred at 0-5° C. (12-15 h), filtered, and then the solid washed with H₂O (10 mL) to afford the desired hydroxamic acid.

N-Hydroxyoxalamide (10)

Yield, 62%; R_f=0.11 (25% MeOH—CHCl₃); mp 158-159° C. (lit.⁹⁾ mp 140-141° C., lit.¹⁰⁾ mp 159° C.); ¹H NMR (DMSO-d₆, 300 MHz) δ7.75 (s, 1H), 8.53 (br s, 2H), the remaining protons were not detected; ¹³C NMR (DMSO-d₆, 75 MHz) δ157.1, 162.0; MS (+CI) 105 [M+1]⁺; M_r (+CI) 105.029 86 [M+1]⁺ (calcd for C₂H₅N₂O₃, 105.030 01). Anal. (C₉H₁₂N₂O₂) C, 59.99; H, 6.71; N, 15.55. Found C, 59.71; H, 6.75; N, 15.37.

Sarcosine Hydroxamic Acid (11)

Yield, 58%; R_f=0.06 (25% MeOH—CHCl₃); mp 140-141° C. (lit.¹¹⁾ mp 140-141° C.); ¹H NMR (DMSO-d₆, 300 MHz) δ2.21 (s, 3H), 2.96 (s, 2H), the remaining protons were not detected; ¹³C NMR (DMSO-d₆, 75 MHz) δ35.7, 51.8, 167.7; MS (+CI) 105 [M+1]⁺; M_r (+CI) 105.066 07 [M+1]⁺ (calcd for C₃H₉N₂O₂, 105.066 40).

N-Benzylglycine Hydroxamic Acid (12)

Yield, 53%; R_f=0.32 (25% MeOH—CHCl₃); mp 142-143° C.; IR (KBr) 3160, 1680, 1609, 1465, 1353, 1284, 1199, 1022 cm⁻¹; ¹H NMR (DMSO-d₆, 300 MHz) δ3.00 (s, 2H), 3.65 (s, 2H), 7.21-7.32 (m, 5H); ¹³C NMR (DMSO-d₆, 75 MHz) δ49.0, 52.3, 126.6, 127.9 (2 C), 128.1 (2 C), 140.2, 167.7; MS (+CD) 181 [M+1]⁺; M_r (+CI) 181.098 01 [M+1]⁺ (calcd for C₉H₁₃N₂O₂, 181.097 70). Anal. (C₉H₁₂N₂O₂) C, 59.99; H, 6.71; N, 15.55. Found C, 59.71; H, 6.75; N, 15.37.

REFERENCES

The following references were cited herein:

• 1) Johnson, G.; Boxer, P. A.; Drummond, J. T.; Boyd, D. K.; Anderson, R. J. Identification and Evaluation of O-Alkyl Substituted Hydroxamic Acids as Potent in vitro Inhibitors of the Hepatic Glycine Cleavage System and Investigation of Their Action on in vivo Central Nervous System Glycine Concentration. Arzneim-Forsch./Drug Res., 1989, 39, 432-437.
• 2) Welch, J. T.; Lin J. Fluoroolefin Containing Dipeptide Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26). Tetrahedron, 1996, 52, 291-304.
• 3) Lee, J.; Kang, M. K.; Chun, M. W.; Jo, Y. J.; Kwak, J. H.; Kim, S. Methionine Analogues as Inhibitors of Methionyl-tRNA Synthetase. Bioorg. Med. Chem. Lett., 1998, 8, 3511-3514.
• 4) Floyd, D. M.; Fritz, A. W.; Pluscec, J.; Weaver, E. R.; Cimarusti, C. M. Monobactams. Preparation of (S)-3-Amino-2-oxoazetidine-1-sulfonic Acids from L-α-Amino-β-hydroxy Acids via Their Hydroxamic Esters. J. Org. Chem., 1982, 47, 5160-5167.
• 5) Mattingly, P. G.; Miller, M. J. Titanium Trichloride Reduction of Substituted N-Hydroxy-2-azetidinones and Other Hydroxamic Acids. J. Org. Chem., 1980, 45, 410-415.
• 6) Gordon, E. M.; Ondetti, M. A.; Pluscec, J.; Cimarusti, C. M.; Bonner, D. P.; Sykes, R. B. O-Sulfated β-Lactam Hydroxamic Acids (Monosulfactams). Novel Monocyclic β-Lactam Antibiotics of Synthetic Origin. J. Am. Chem. Soc., 1982, 104, 6053-6060.
• 7) Matveev, B. V.; Tsybaeva, G. G. Synthesis and Polarographic Reduction of Aliphatic Amino Hydroxamic Acids. J. Gen. Chem. USSR (Engl. Transl.), 1964, 34, 2512-2516.
• 8) Knobler, Y.; Bittner, S.; Frankel, M. Reaction of N-Carboxy-α-Amino-acid Anhydrides with Hydrochlorides of Hydroxylamine, O-Alkylhydroxylamines, and Amines; Syntheses of Amino-hydroxamic Acids, Amido-oxy-peptides, and α-Amino-acid Amides. J. Chem. Soc., 1964, 3941-3951.
• 9) Petyunin, G. P.; Erling, R.; Naumann, K.; Kulikova, D. A.; Ostapchuk, N. V. Amides and Hydrazides of Oxalic Acid XXXVII. Synthesis and Biological Activity of Substituted Carbamidohydroxamic Acids. Pharm. Chem. J. (Engl. Transl.), 1978, 12, 780-782.
• 10) Houben; Schmidt. Chem Ber., 1913, 46, 3622.
• 11) Harmon, R. E.; Rizzo, V. L.; Gupta, S. K. Synthesis of 3-Hydroxy-4-Imidazolidinones (1a, b). J. Heterocycl. Chem. 1970, 7, 439-442.

All references cited herein are incorporated by reference. While this invention has been described fully and completely, it should be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. Although the invention has been disclosed with reference to its preferred embodiments, from reading this description those of skill in the art may appreciate changes and modification that may be made which do not depart from the scope and spirit of the invention as described above and claimed hereafter.

Claims

1. An anti-mycobacterial composition comprising a therapeutically effective amount of at least one compound of the formula (I):

2. The composition of claim 1, wherein the at least one compound of formula (I) is optically pure, a racemic mixture, or an optical active mixture of pure enantiomers.

3. The composition of claim 1, where at least one compound of formula (I) is selected from the group consisting of glycine hydroxamic acid, glycine hydroxamic acid hydrochloride, glycine hydroxamic trifluoracetic acid, O-methylglycine hydroxamic acid trifluoracetic acid, D-alanine hydroxamic acid hydrochloride, L-alanine hydroxamic acid hydrochloride, N-hydroxyoxalamide, sarcosine hydroxamic acid, and D-methionine hydroxamic acid.

4. The composition of claim 1, wherein the at least one compound of formula (II) is selected from the group consisting of hydroxylamine, methylhydroxylamine and ethylhydroxylamine.

5. The composition of claim 1, wherein the at least one compound of formula (II) is hydroxylamine.

6. The composition of claim 1, wherein R1, R2, R3, R4, R5, R6 and R7 are independently unsubstituted or substituted, if substituted the substituents comprise at least one electron withdrawing substituent or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

7. The composition of claim 6, wherein R8, R9 and R10 are independently unsubstituted or substituted with at least one electron withdrawing or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

8. An anti-mycobacterial composition comprising a therapeutically effective amount of at least one compound of the formula (I):

9. The composition of claim 8, wherein the at least one compound of formula (I) is optically pure, a racemic mixture, or an optical active mixture of pure enantiomers.

10. The composition of claim 8, where at least one compound of formula (I) is selected from the group consisting of glycine hydroxamic acid, glycine hydroxamic acid hydrochloride, glycine hydroxamic trifluoracetic acid, O-methylglycine hydroxamic acid trifluoracetic acid, D-alanine hydroxamic acid hydrochloride, L-alanine hydroxamic acid hydrochloride, N-hydroxyoxalamide, sarcosine hydroxamic acid, and D-methionine hydroxamic acid.

11. The composition of claim 8, wherein the at least one compound of formula (II) is selected from the group consisting of hydroxylamine, methylhydroxylamine and ethylhydroxylamine.

12. The composition of claim 8, wherein the at least one compound of formula (II) is hydroxylamine.

13. The composition of claim 8, wherein R1, R2, R3, R4, R5, R6 and R7 are independently unsubstituted or substituted, if substituted the substituents comprise at least one electron withdrawing substituent or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

14. The composition of claim 13, wherein R8, R9 and R10 are independently unsubstituted or substituted with at least one electron withdrawing or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

15. The composition of claim 8, wherein the wt. % ratio of compounds of formula (I) to compounds of formula (II) is between about 100:1 and about 10:1 and wherein the therapeutically effective amount is between about 125 μg/mL and about 1 μg/mL for each hydroxamate used in the composition and between about 125 μg/mL and about 1 μg/mL for each hydroxylamine used in the composition.

16. A method for treating mycobacterial infections in animals comprising the step of: administering to an animal including a human on an individual, continuous, periodic, or intermittent basis or according to an individual, continuous, periodic, or intermittent administration protocol, an therapeutically effective amount composition having anti-mycobacterial activity including at least one compound of formula (I):

17. The method of claim 16, wherein the at least one compound of formula (I) is optically pure, a racemic mixture, or an optical active mixture of pure enantiomers.

18. The method of claim 16, where at least one compound of formula (I) is selected from the group consisting of glycine hydroxamic acid, glycine hydroxamic acid hydrochloride, glycine hydroxamic trifluoracetic acid, O-methylglycine hydroxamic acid trifluoracetic acid, D-alanine hydroxamic acid hydrochloride, L-alanine hydroxamic acid hydrochloride, N-hydroxyoxalamide, sarcosine hydroxamic acid, and D-methionine hydroxamic acid.

19. The method of claim 16, wherein the at least one compound of formula (II) is selected from the group consisting of hydroxylamine, methylhydroxylamine and ethylhydroxylamine.

20. The method of claim 16, wherein the at least one compound of formula (II) is hydroxylamine.

21. The method of claim 16, wherein R1, R2, R3, R4, R5, R6 and R7 are independently unsubstituted or substituted, if substituted the substituents comprise at least one electron withdrawing substituent or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

22. The method of claim 21, wherein R8, R9 and R10 are independently unsubstituted or substituted with at least one electron withdrawing or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

23. The method of claim 16, wherein a wt. % ratio of compounds of formula (I) to compounds of formula (II) is between about 100:1 and about 1:1 and wherein the therapeutically effective amount is between about 125 μg/mL and about 1 μg/mL for each hydroxamate used in the composition and between about 125 μg/mL and about 1 μg/mL for each hydroxylamine used in the composition.

24. A method for treating mycobacterial infections in animals comprising the step of: administering to an animal including a human on an individual, continuous, periodic, or intermittent basis or according to an individual, continuous, periodic, or intermittent administration protocol, an therapeutically effective amount composition having anti-mycobacterial activity including at least one compound of formula (I):

25. The method of claim 24, wherein the at least one compound of formula (I) is optically pure, a racemic mixture, or an optical active mixture of pure enantiomers.

26. The method of claim 24, where at least one compound of formula (I) is selected from the group consisting of glycine hydroxamic acid, glycine hydroxamic acid hydrochloride, glycine hydroxamic trifluoracetic acid, O-methylglycine hydroxamic acid trifluoracetic acid, D-alanine hydroxamic acid hydrochloride, L-alanine hydroxamic acid hydrochloride, N-hydroxyoxalamide, sarcosine hydroxamic acid, and D-methionine hydroxamic acid.

27. The method of claim 24, wherein the at least one compound of formula (II) is selected from the group consisting of hydroxylamine, methylhydroxylamine and ethylhydroxylamine.

28. The method of claim 24, wherein the at least one compound of formula (II) is hydroxylamine.

29. The method of claim 24, wherein R1, R2, R3, R4, R5, R6 and R7 are independently unsubstituted or substituted, if substituted the substituents comprise at least one electron withdrawing substituent or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

30. The method of claim 29, wherein R8, R9 and R10 are independently unsubstituted or substituted with at least one electron withdrawing or at least one electron donating substituent selected from the group consisting of OR8, SR8, S(O)R8, S(O)2R8, NH2, NHR8, NR8(R9), NHNH2, N(R8)NH2, N(R8)N(R9)H, N(R8)N(R9)(R10), NOH, NOR8, C(O)R8, CO2H, CO2R8, CN, C(O)NH2, C(O)NHR8, C(O)NR8(R9), OC(O)NH2, OC(O)NHR8, OC(O)NR8(R9), C(NR8)N(H)R9, C(NR8)NR9(R10) and mixtures or combinations thereof, where R8, R9 and R10 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl, linear or branched lower alkenyl, linear or branched lower alkynl, linear or branched aryl lower alkyl, aryl, linear or branched heterocyclic lower alkyl, linear or branched heterocyclic lower cycloalkyl, linear or branched lower cycloalkyl, linear or branched lower cycloalkyl lower alkyl and mixtures or combinations thereof.

31. The method of claim 24, wherein the wt. % ratio of compounds of formula (I) to compounds of formula (II) is between about 100:1 and about 10:1 and wherein the therapeutically effective amount is between about 125 μg/mL and about 1 μg/mL for each hydroxamate used in the composition and between about 125 μg/mL and about 1 μg/mL for each hydroxylamine used in the composition.

32. The composition of claim 1, wherein a wt. % ratio of compounds of formula (I) to compounds of formula (II) is between about 100:1 and about 1:1 and wherein the therapeutically effective amount is between about 125 μg/mL and about 1 μg/mL for each hydroxamate used in the composition and between about 125 μg/mL and about 1 μg/mL for each hydroxylamine used in the composition.